New hope for chinese women with hard-to-treat endometrial cancer

NCT ID NCT07108270

First seen Jan 10, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This study tests a drug called dostarlimab combined with chemotherapy (carboplatin and paclitaxel) in 30 Chinese women with advanced or recurrent endometrial cancer that has specific genetic markers (dMMR/MSI-H). The goal is to see if the treatment shrinks tumors and keeps them from growing for at least a year. Participants will receive the drug combo followed by dostarlimab alone, and researchers will monitor safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS, ENDOMETRIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    Jinan, Shandong, 250117, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.